Abstracts tagged "Disease-modifying antirheumatic drugs"

Abstract Number: 479 • 2013 ACR/ARHP Annual Meeting
Attainment Of Remission, Functional, and Quality Of Life Improvements With Golimumab Treatment In Rheumatoid Arthritis Are Associated With Patient Expectations
B Dasgupta¹, B Combe², I Louw³, J Wollenhaupt⁴, C Zerbini⁵, A Beaulieu⁶, H Schulze-Koops⁷, P Durez⁸, V Wolff⁹, R Yao¹⁰, HH Weng¹⁰, M Govoni¹¹ and N Vastesaeger¹², ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Lapeyronie, Montpellier, France, ³Panorama Medical Centre, Cape Town, South Africa, ⁴Schön-Klinik, Hamburg, Germany, ⁵Hospital Heliópolis, Serviço de Reumatologia, São Paulo, Brazil, ⁶Centre de Rhumatologie, St-Louis, QC, Canada, ⁷University of Munich, Munich, Germany, ⁸Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁹Hospital del Salvador, Santiago, Chile, ¹⁰Merck & Co., Inc., Whitehouse Station, NJ, ¹¹MSD Italy, Rome, Italy, ¹²Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Golimumab (GLM) and other tumor necrosis factor antagonists are used as add-on therapy for patients with rheumatoid arthritis (RA) who have not responded to…
Abstract Number: 446 • 2013 ACR/ARHP Annual Meeting
Remission Rates During Golimumab Treatment For Rheumatoid Arthritis Are Associated With Differences In Baseline Disease States Across Geographic Regions
P Durez¹, K Pavelka², M Lazaro³, A Garcia Kutzbach⁴, R Moots⁵, H Amital⁶, R Yao⁷, M Govoni^8,9, N Vastesaeger¹⁰ and HH Weng⁷, ¹Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Revmatologicky Ustav, Praha, Czech Republic, ³IARI Instituto de Asistencia Reumatologica Integral, Buenos Aires, Argentina, ⁴AGAR Francisco Marroquin University, Guatemala City, Guatemala, ⁵University Hospital Aintree, Liverpool, United Kingdom, ⁶Sheba Medical Center, Tel-Hashomer, Israel, ⁷Merck & Co., Inc., Whitehouse Station, NJ, ⁸MSD Italy, Rome, Italy, ⁹Merck Sharp & Dohme, Rome, Italy, ¹⁰Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Regional differences in practice patterns and access to biologic treatment for rheumatoid arthritis (RA) may lead to regional differences in baseline disease characteristics, which…
Abstract Number: 343 • 2013 ACR/ARHP Annual Meeting
Conventional Dmards For Psoriatic Arthritis: Data On 1351 Treatment Courses With Methotrexate, Sulfasalazine and Leflunomide
Elisabeth Lie¹, Karen M. Fagerli¹, Erik Rødevand², Synnøve Kalstad³, Knut Mikkelsen⁴, Ada Wierød⁵, Désirée van der Heijde⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ³Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway, ⁴Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital Drammen, Drammen, Norway, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Methotrexate (MTX), sulfasalazine (SSZ) and leflunomide (LEF) are recommended treatments for PsA patients with active peripheral arthritis. In the publication of a recent negative…
Abstract Number: 205 • 2013 ACR/ARHP Annual Meeting
Temporal Trends In The Prescribing Of Disease Modifying Anti-Rheumatic Drugs For Rheumatoid Arthritis and The Impact Of Guidelines
Gemma L Wallace¹, C. J. Edwards², Nigel K. Arden³, Daniel Prieto-Alhambra⁴ and Andrew Judge⁵, ¹NDORMS, University of Oxford, Oxford, United Kingdom, ²Rheumatology, University Hospital Southampton, Southampton, United Kingdom, ³NDORMS; MRC Lifecourse Epidemiology Unit, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁴Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, ⁵Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom
Background/Purpose: Disease modifying anti-rheumatic drugs (DMARDs) are standard initial treatments for rheumatoid arthritis (RA). Many RA treatment guidelines have been published including from the American…
Abstract Number: 187 • 2013 ACR/ARHP Annual Meeting
The Health and Economic Consequences Of Delay In Starting Disease-Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Danny Liew, Mark Tacey and Sharon Van Doornum, Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia
Background/Purpose: Several international studies suggest that the time between symptom onset and DMARD initiation in RA patients is longer than is considered optimal. We sought…
Abstract Number: 404 • 2012 ACR/ARHP Annual Meeting
Remission is a Difficult Target in Clinical Practice When RA Disease Is Established
Till Uhlig¹, Elisabeth Lie², Cecillie Kaufmann³, Erik Rødevand⁴, Knut Mikkelsen⁵, Synnøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology department, Vestre Viken, Drammen, Norway, ⁴Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission is the treatment target in rheumatoid arthritis (RA) and several composite indices are available for evaluation of remission and low disease activity…
Abstract Number: 211 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review
JA Martinez-Lopez Sr.¹, J. Graña Sr.², Santiago Muñoz-Fernandez³, I. Rua-Figueroa⁴, José M. Pego-Reigosa⁵, Estíbaliz Loza Sr.⁶ and SER group for the study of systemic autoimmune diseases⁷, ¹Fundacion Jimenez Diaz, Madrid, Spain, ²Hospital Juan Canalejo, Spain, ³Unit Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁴Rheumatology, Hospital de GC Dr Negrin, Las Palmas GC, Spain, ⁵Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ⁶Research Unit. Sociedad Española de Reumatología, Madrid, Spain, ⁷Madrid
Background/Purpose: The aim of this study was to systematically review the efficacy and safety of available drugs in patients with polymyositis (PM) or dermatomyositis (DM)Methods:…
Abstract Number: 196 • 2012 ACR/ARHP Annual Meeting
Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy
Alireza Meysami¹, Kevin F. Spratt² and Christopher M. Burns³, ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Department of Orthopaedic Surgery, Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth Medical School, Lebanon, NH
· Background/Purpose: Sarcoidosis is characterized by a variable clinical presentation. DMARDs and biologics have been used for resistant and/or organ-threatening disease. We analyzed the cases…
Abstract Number: 112 • 2012 ACR/ARHP Annual Meeting
Time-Integrated Synovitis Activity Assessed by Power Doppler Ultrasound Significantly Correlates with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Methotrexate Alone but Not in Those Treated with TNF Antagonists
Kei Ikeda, Daiki Nakagomi, Yoshie Sanayama, Mieko Yamagata, Ayako Okubo, Taro Iwamoto, Hirotoshi Kawashima, Kentaro Takahashi and Hiroshi Nakajima, Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan
Background/Purpose: Although a number of studies have shown a higher sensitivity of ultrasound than clinical joint examination in detecting synovitis in patients with rheumatoid arthritis…
Abstract Number: 2662 • 2012 ACR/ARHP Annual Meeting
Tightening up: Musculoskeletal Ultrasound Could Further Individualise Treatment Decisions in Early Rheumatoid Arthritis Patients Treated by a Step-up DMARD Escalation Regimen
James Dale¹, David Purves², Alex McConnachie², Duncan Porter³ and Iain B. McInnes⁴, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom, ³Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom, ⁴Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Treat-to-target (T2T) strategies have significantly improved outcomes in early rheumatoid arthritis (RA). Treatment escalation is usually guided by a disease activity score; however, modern…
Abstract Number: 1840 • 2012 ACR/ARHP Annual Meeting
Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti-Rheumatic Drugs
Jeffrey R. Curtis¹, Genevieve Gauthier², Robert Hiscock² and Frank Zhang³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Analysis Group, Inc., Montreal, QC, Canada, ³Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). Oral disease modifying anti-rheumatic drugs (DMARDs) are often used as a first-line treatment…
Abstract Number: 1843 • 2012 ACR/ARHP Annual Meeting
Predictors of Starting and Stopping Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: A 23 Year Longitudinal Cohort
Daniel H. Solomon¹, Edward H. Yelin², Jeffrey N. Katz³, Chris Tonner⁴, M. Alan Brookhart⁵, Seoyoung C. Kim⁶, Bing Lu⁷ and John Z. Ayanian⁸, ¹Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Medicine, UC San Francisco, San Francisco, CA, ³Rheumatology and Orthopedics, Brigham & Women's Hospital, Boston, MA, ⁴Medicine, UCSF, San Francisco, CA, ⁵University of North Carolina, Chapel Hill, NC, ⁶Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: DMARDs are the standard of care for rheumatoid arthritis (RA), however multiple studies find that not all patients use these agents. We examined predictors…
Abstract Number: 1844 • 2012 ACR/ARHP Annual Meeting
Inequities in Access to Biologic Disease-Modifying Anti-Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries
Polina Putrik¹, Sofia Ramiro², Milena Pavlova³, Tore K. Kvien⁴, Tuulikki Sokka⁵, Till Uhlig⁴, Annelies Boonen⁶ and Equity In Access To Treatment of RA Across Europe⁷, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ³Health Services Research, Maastricht University, Maastricht, Netherlands, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁷European Region
Background/Purpose: In the treatment of patients with RA, EULAR recommends to initiate biologic DMARDs after failing synthetic DMARDs. However, biologics are costly, and it is…
Abstract Number: 1845 • 2012 ACR/ARHP Annual Meeting
Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis
Polina Putrik¹, Sofia Ramiro², Tore K. Kvien³, Tuulikki Sokka⁴, Till Uhlig³, Annelies Boonen⁵ and Equity in Clinical Eligibility Criteria for RA treatment⁶, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶European Region
Background/Purpose: In the treatment of patients with RA, strategies that include biologics have resulted in a better outcome for patients with regard to disease activity,…
Abstract Number: 1761 • 2012 ACR/ARHP Annual Meeting
Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor
Seung Y. Chu¹, Karen Yeter², Roshan Kotha³, Erik Pong¹, Yvonne Miranda¹, Hsing Chen¹, Sung-Hyung Lee¹, Irene Leung¹, John R. Desjarlais¹, William Stohl² and David E. Szymkowski⁴, ¹Xencor, Inc., Monrovia, CA, ²Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ³Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Biotherapeutics, Xencor, Inc., Monrovia, CA
Background/Purpose: XmAb®5871 is a humanized and Fc-engineered antibody that coengages CD19, part of the B cell receptor (BCR) complex, with the inhibitory receptor FcγRIIb (CD32b).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.